Subscribe
istock-183060916
oonal / iStockphoto.com
26 September 2017Americas

Amgen secures $70m in biosimilar clash with Hospira

Amgen has secured $70 million in damages from a jury in a biosimilar dispute with Hospira.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Federal Circuit rejects Amgen biosimilar discovery request
11 August 2017   The US Court of Appeals for the Federal Circuit has rejected a request by Amgen to compel discovery from Hospira over a biosimilar.
Americas
Hospira appeals against $70m Amgen verdict
2 October 2017   Hospira has appealed against a verdict which saw Amgen secure $70 million in damages over a biosimilar dispute between the two companies.
Big Pharma
Hospira suffers setback as two patents invalidated
21 December 2018   A US district court has invalidated two patents owned by American pharmaceutical firm Hospira, in a victory for German healthcare company Fresenius Kabi.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Federal Circuit rejects Amgen biosimilar discovery request
11 August 2017   The US Court of Appeals for the Federal Circuit has rejected a request by Amgen to compel discovery from Hospira over a biosimilar.
Americas
Hospira appeals against $70m Amgen verdict
2 October 2017   Hospira has appealed against a verdict which saw Amgen secure $70 million in damages over a biosimilar dispute between the two companies.
Big Pharma
Hospira suffers setback as two patents invalidated
21 December 2018   A US district court has invalidated two patents owned by American pharmaceutical firm Hospira, in a victory for German healthcare company Fresenius Kabi.

More on this story

Americas
Federal Circuit rejects Amgen biosimilar discovery request
11 August 2017   The US Court of Appeals for the Federal Circuit has rejected a request by Amgen to compel discovery from Hospira over a biosimilar.
Americas
Hospira appeals against $70m Amgen verdict
2 October 2017   Hospira has appealed against a verdict which saw Amgen secure $70 million in damages over a biosimilar dispute between the two companies.
Big Pharma
Hospira suffers setback as two patents invalidated
21 December 2018   A US district court has invalidated two patents owned by American pharmaceutical firm Hospira, in a victory for German healthcare company Fresenius Kabi.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York